Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 3/20 | 1.00 |
| ▸ | RAB9A | P51151 | 13/20 | 0.68 |
| ▸ | NPC1 | O15118 | 10/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.65 |
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | GLA | P06280 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4664159 | 0.89 | LDHA (0.80) | LDHARAB9ANPC1SMN1; SMN2HTT | |
| SCHEMBL4011536 | 0.88 | LDHA (0.78) | LDHARAB9ANPC1SMN1; SMN2HTT | |
| SCHEMBL15195866 | 0.86 | LDHA (0.76) | LDHARAB9ANPC1SMN1; SMN2HTT | |
| SCHEMBL23932785 | 0.85 | LDHA (0.74) | LDHARAB9ANPC1SMN1; SMN2HTT | |
| SCHEMBL22894148 | 0.84 | LDHA (0.73) | LDHARAB9ANPC1SMN1; SMN2HTT | |
| SCHEMBL13343673 | 0.84 | LDHA (0.73) | LDHARAB9ANPC1SMN1; SMN2HTT | |
| SCHEMBL29609444 | 0.84 | LDHA (0.73) | LDHARAB9ANPC1SMN1; SMN2HTT | |
| SCHEMBL14907231 | 0.84 | MAPT (0.74) | LDHARAB9ANPC1SMN1; SMN2HTT | |
| SCHEMBL5314650 | 0.83 | RAB9A (0.85) | LDHARAB9ANPC1SMN1; SMN2HTT | |
| SCHEMBL1747915 | 0.83 | LDHA (0.71) | LDHARAB9ANPC1SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441755-B2 | Galactoside inhibitor of galectins | GALECTO BIOTECH AB (DK) | 2025-10-14 | — | — | US | disclosed |
| US-20220259251-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2022-08-18 | — | — | US | disclosed |
| EP-3994135-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | Galecto Biotech AB (DK) | 2022-05-11 | — | — | EP | disclosed |
| CN-114450282-A | Novel galactoside inhibitors of galectins | 格莱克特生物技术公司 | 2022-05-06 | — | — | CN | disclosed |
| WO-2021004940-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2021-01-14 | — | — | WO | disclosed |
| WO-2021004940-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2021-01-14 | — | — | WO | disclosed |
| US-20160101104-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-14 | — | — | US | disclosed |
| US-20150342935-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150094309-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2015-04-02 | — | — | US | disclosed |
| EP-2429993-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INT (DE) | 2015-01-21 | — | — | EP | disclosed |
| US-20060029946-A1 | Live cell biosensors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-02-09 | — | — | US | disclosed |
| WO-2005106868-A1 | METAL CHELATES AND THEIR USE IN OPTICAL RECORDING MEDIA HAVING HIGH STORAGE CAPACITY | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2005-11-10 | — | — | WO | disclosed |
| WO-2005088308-A2 | FLUORESCENT SIGNAL EMITTING LIVE CELL BIOSENSOR MOLECULES AND DYES FOR DETECTION AND QUANTIFICATION OF PROTEIN ACTIVITIES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20050170517-A1 | Materials for enhancing staining of biopolymers in matrices | INVITROGEN CORPORATION (US) | 2005-08-04 | — | — | US | disclosed |
| US-6878551-B2 | For proteins/polypeptides within polyacrylamide matrix; mass spectrometry | INVITROGEN CORPORATION (US) | 2005-04-12 | — | — | US | disclosed |
| US-20040038418-A1 | Materials for enhancing staining of biopolymers in matrices | INVITROGEN CORPORATION | 2004-02-26 | — | — | US | disclosed |
| US-6635489-B2 | Sensitizing the matrix with heteroaromatic compounds, contacting with reduceable metal salts to stain and detecting | INVITROGEN CORPORATION | 2003-10-21 | — | — | US | disclosed |
| EP-1344055-A1 | MATERIALS FOR ENHANCING STAINING OF BIOPOLYMERS IN MATRICES | INVITROGEN CORPORATION (US) | 2003-09-17 | — | — | EP | disclosed |
| US-20020137222-A1 | Materials for enhancing staining of biopolymers in matrices | INVITROGEN CORPORATION | 2002-09-26 | — | — | US | disclosed |
| WO-2002042764-A1 | MATERIALS FOR ENHANCING STAINING OF BIOPOLYMERS IN MATRICES | INVITROGEN CORPORATION (US) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220259251-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | LGALS1, LGALS3, LGALS3BP | LDHA 1917/4885RAB9A 2538/4885NPC1 1143/4885 |
| US-12441755-B2 | Galactoside inhibitor of galectins | LGALS1, LGALS3, LGALS2 | LDHA 1715/4885RAB9A 2901/4885NPC1 1125/4885 |
| US-20160101104-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | LDHA 2795/4885RAB9A 333/4885NPC1 896/4885 |
| US-20150342935-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | LDHA 2795/4885RAB9A 333/4885NPC1 896/4885 |
| US-20150094309-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | LDHA 2795/4885RAB9A 333/4885NPC1 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.